{"url_path":"/sec/pasg/8-k/2026-06-24/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1787297/0001104659-26-077306-index.html","accession_number":"0001104659-26-077306","cik":"0001787297","ticker":"PASG","issuer_name":"Passage BIO, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787297/0001104659-26-077306-index.html","primary_entity_key":"0001787297","primary_entity_name":"Passage BIO, Inc."},"word_count":149,"has_tables":true,"body_markdown":"**Item 1.02. Termination of a Material Definitive Agreement.**\n\n \n\nOn June 23, 2026, the Company delivered written\nnotice to Catalent Maryland, Inc. (“**Catalent**”) of the Company’s election to terminate, pursuant to\nSection 20.1(b)(ii) therein, the Amended and Restated Development Services and Clinical Supply Agreement by and between the\nCompany and Catalent, dated as of November 9, 2023 (the “**Catalent Agreement**”) in its entirety, with such\ntermination effective as of June 23, 2026.\n\n \n\nThe Catalent Agreement governed the provision\nof development services and clinical supply manufacturing services, including the manufacture of bulk drug substance and drug product,\nby Catalent to the Company in connection with the Company’s gene therapy programs, including PBFT02. The Company determined to terminate\nthe Catalent Agreement in connection with the wind-down of its gene therapy programs and the proposed Merger.\n\n \n\nIn connection with the termination, the Company\nwill not be obligated to pay Catalent a termination fee."}